title: Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin.
abstract: The study aims to map plasma gelsolin (pGSN) levels in diabetic humans and mice models of type II diabetes and to evaluate the efficacy of gelsolin therapy in improvement of diabetes in mice. We report that pGSN values decrease by a factor of 0.45 to 0.5 in the blood of type II diabetic humans and mice models. Oral glucose tolerance test in mice models showed that subcutaneous administration of recombinant pGSN and its F-actin depolymerizing competent versions brought down blood sugar levels comparable to Sitagliptin, a drug used to manage hyperglycemic condition. Further, daily dose of pGSN or its truncated versions to diabetic mice for a week kept sugar levels close to normal values. Also, diabetic mice treated with Sitagliptin for 7 days, showed increase in their pGSN values with the decrease in blood glucose as compared to their levels at the start of treatment. Gelsolin helped in improving glycemic control in diabetic mice. We propose that gelsolin level monitoring and replacement of F-actin severing capable gelsolin(s) should be considered in diabetic care.
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Neeraj
authors.initials: N
authors.lastname: Khatri
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Amin
authors.initials: A
authors.lastname: Sagar
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Nagesh
authors.initials: N
authors.lastname: Peddada
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Vikas
authors.initials: V
authors.lastname: Choudhary
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Bhupinder Singh
authors.initials: BS
authors.lastname: Chopra
authors.affiliation: Department of Bioscience and Biotechnology, Banasthali University, Rajasthan 304022, India.
authors.forename: Veena
authors.initials: V
authors.lastname: Garg
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.forename: Renu
authors.identifier: 0000-0001-5573-7956
authors.initials: R
authors.lastname: Garg
authors.affiliation: CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.
authors.lastname: Ashish
mesh_terms: D000199:Actins / Q000378:metabolism*; D000328:Adult; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D016022:Case-Control Studies; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D059305:Diet, High-Fat; D015536:Down-Regulation; D005260:Female; D018260:Gelsolin / Q000097:blood* / Q000494:pharmacology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010446:Peptide Fragments / Q000494:pharmacology*; D058105:Polymerization; D011719:Pyrazines / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D000068900:Sitagliptin Phosphate; D013311:Streptozocin; D013997:Time Factors; D014230:Triazoles / Q000494:pharmacology
chemical_list: D000199:Actins; D015415:Biomarkers; D001786:Blood Glucose; D018260:Gelsolin; D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011719:Pyrazines; D011994:Recombinant Proteins; D014230:Triazoles; D013311:Streptozocin; D000068900:Sitagliptin Phosphate